Please provide your email address to receive an email when new articles are posted on . Phase 1 pharmacokinetics results showed comparability between SB17 and ustekinumab. Phase 3 results of SB17 will ...
July 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback